GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HighTide Therapeutics Inc (HKSE:02511) » Definitions » Stock Based Compensation

HighTide Therapeutics (HKSE:02511) Stock Based Compensation : HK$129.33 Mil (TTM As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is HighTide Therapeutics Stock Based Compensation?

HighTide Therapeutics's Stock Based Compensation for the six months ended in Jun. 2024 was HK$58.18 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2024 was HK$129.33 Mil.


HighTide Therapeutics Stock Based Compensation Historical Data

The historical data trend for HighTide Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HighTide Therapeutics Stock Based Compensation Chart

HighTide Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Stock Based Compensation
8.94 28.61 102.26

HighTide Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Stock Based Compensation Get a 7-Day Free Trial 12.04 17.15 31.12 71.15 58.18

HighTide Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$129.33 Mil.


HighTide Therapeutics Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of HighTide Therapeutics's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


HighTide Therapeutics Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Ganli Second Road, 18B-102, Zhonghaixin Innovation Industry City, Jihua Neighborhood, Longgang District, Guangdong, Shenzhen, CHN, 518112
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The company has developed a product pipeline of five product candidates in-house, covering nine indications in metabolic and digestive diseases among which, five are at clinical-stage. The Core Product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.
Executives
Li Tan 2202 Interest of your spouse
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. 2501 Other
Li Li 2201 Interest of corporation controlled by you
Ma Lixiong 2101 Beneficial owner
Liu Liping 2101 Beneficial owner
The Core Trust Company Limited
Shan Miao 2201 Interest of corporation controlled by you
Medi Prosperity Capital Inc. 2201 Interest of corporation controlled by you
Hepalink Healthcare Partners I L.p 2201 Interest of corporation controlled by you
Hepalink Biotechnology Ii Limited 2101 Beneficial owner
Hepalink (hong Kong) Limited 2201 Interest of corporation controlled by you
Wisdom Spring Group Limited
Tct (bvi) Limited
Baiyi Capital Limited 2101 Beneficial owner
Lai Hoi Man 2201 Interest of corporation controlled by you

HighTide Therapeutics Headlines

No Headlines